Literature DB >> 18347935

The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Hakan Camlica1, Derya Duranyildiz, Hilal Oguz, Ethem Nezih Oral, Vildan Yasasever.   

Abstract

The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum MIF, CEA, CA 19-9 levels and their various combinations in patients with gastric cancer. Study group consists of pathologically verified, gastric cancer (n = 63) and apparently healthy controls (n = 50). Serum MIF concentrations were determined by enzyme-linked immunosorbent assay (ELISA). Serum values of patients were significantly higher than the controls (p = 0.011). Diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their various combinations. The best results were achieved with the marker combination of MIF-CEA-CA 19-9 and MIF-CEA combination. In our opinion, the combination of the markers MIF-CEA is a valuable diagnostic tool for gastric cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18347935     DOI： 10.1007/s12253-008-9002-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  25 in total

1.  MCA in patients with breast cancer: correlation with CEA and CA15-3.

Authors:  R Molina; X Filella; P Mengual; M Prats; G Zanon; M Daniels; A M Ballesta
Journal:  Int J Biol Markers       Date:  1990 Jan-Mar       Impact factor: 2.659

Review 2.  Molecular biological observations in gastric cancer.

Authors:  E Tahara; S Semba; H Tahara
Journal:  Semin Oncol       Date:  1996-06       Impact factor: 4.929

3.  Elevated prostatic acid phosphatase: a prognostic factor for stage C adenocarcinoma of the prostate.

Authors:  R J Babaian; R P Orlando
Journal:  J Urol       Date:  1986-11       Impact factor: 7.450

4.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

5.  Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis.

Authors:  S M Akbar; M Abe; H Murakami; K Tanimoto; T Kumagi; Y Yamashita; K Michitaka; N Horiike; M Onji
Journal:  Cancer Lett       Date:  2001-10-10       Impact factor: 8.679

6.  Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.

Authors:  M T del Vecchio; S A Tripodi; F Arcuri; L Pergola; L Hako; R Vatti; M Cintorino
Journal:  Prostate       Date:  2000-09-15       Impact factor: 4.104

7.  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.

Authors:  B R Bloom; B Bennett
Journal:  Science       Date:  1966-07-01       Impact factor: 47.728

8.  Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression.

Authors:  C Munaut; J Boniver; J-M Foidart; M Deprez
Journal:  Neuropathol Appl Neurobiol       Date:  2002-12       Impact factor: 8.090

9.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Fam Pract       Date:  2004-02       Impact factor: 2.267

10.  Specific carcinoembryonic antigens of the human digestive system.

Authors:  P Gold; S O Freedman
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

2.  CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Authors:  Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

3.  Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.

Authors:  Guo-Qing Li; Juan Xie; Xiao-Yong Lei; Li Zhang
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

4.  Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Authors:  Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-25       Impact factor: 4.553

5.  Macrophage migration inhibitory factor expression in cervical cancer.

Authors:  Mathias Krockenberger; Jörg B Engel; Julia Kolb; Yvonne Dombrowsky; Sebastian F M Häusler; Nico Kohrenhagen; Johannes Dietl; Jörg Wischhusen; Arnd Honig
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-14       Impact factor: 4.553

6.  A role for NRAGE in NF-kappaB activation through the non-canonical BMP pathway.

Authors:  Nicholas Matluk; Jennifer A Rochira; Aldona Karaczyn; Tamara Adams; Joseph M Verdi
Journal:  BMC Biol       Date:  2010-01-25       Impact factor: 7.431

7.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

8.  Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas.

Authors:  N J Shimwell; D G Ward; Y Mohri; T Mohri; L Pallan; M Teng; Y C Miki; M Kusunoki; O Tucker; W Wei; J Morse; P J Johnson
Journal:  Br J Cancer       Date:  2012-09-11       Impact factor: 7.640

9.  Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma.

Authors:  Mariana Barbosa DE Souza; Otávio Alberto Curioni; Jossi Ledo Kanda; Marcos Brasilino DE Carvalho
Journal:  Oncol Lett       Date:  2014-09-09       Impact factor: 2.967

10.  Chronic macrophage migration inhibitory factor exposure induces mesenchymal epithelial transition and promotes gastric and colon cancers.

Authors:  Katherine T Morris; Robert A Nofchissey; Irina V Pinchuk; Ellen J Beswick
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.